From Clinical Trial Efficacy to Real-World Effectiveness First Ajovy® ▼ (fremanezumab) Data from European Real World Evidence Program | Business Wire

AMSTERDAM–( BUSINESS WIRE )–8 November 2021, Teva Germany (GmbH) presented at the DGN Congress 2021 the first interim analysis results of the FINESSE study aiming to provide real-world evidence of fremanezumab treatment outcomes by evaluating effectiveness in routine clinical practice.

Read the source article at businesswire.com
2021-11-08 00:00:00